CAS: 114343-74-7 - (1R,2S,3S,4R,4aS,8aS)-Decahydro-4-[(1E,3E)-5-hydroxy-3-methyl-1,3-pentadien-1-yl]-3,4a,8,8-tetramethyl-1,2,3-naphthalenetriol
Formula:C20H34O4
InChI:InChI=1S/C20H34O4/c1-13(9-12-21)7-8-14-19(4)11-6-10-18(2,3)16(19)15(22)17(23)20(14,5)24/h7-9,14-17,21-24H,6,10-12H2,1-5H3/b8-7+,13-9+/t14-,15-,16+,17+,19-,20+/m1/s1
InChI key:InChIKey=RMAJUEUHZWCNQM-UONADXLZSA-N
SMILES:OCC=C(C=CC1C(O)(C)C(O)C(O)C2C(C)(C)CCCC12C)C
- Synonyms:
- (1R,2S,3S,4R,4aS,8aS)-Decahydro-4-[(1E,3E)-5-hydroxy-3-methyl-1,3-pentadien-1-yl]-3,4a,8,8-tetramethyl-1,2,3-naphthalenetriol
- 1,2,3-Naphthalenetriol, decahydro-4-[(1E,3E)-5-hydroxy-3-methyl-1,3-pentadienyl]-3,4a,8,8-tetramethyl-, (1R,2S,3S,4R,4aS,8aS)-
- 1,2,3-Naphthalenetriol,decahydro-4-(5-hydroxy-3-methyl-1,3-pentadienyl)-3,4a,8,8-tetramethyl-, [1R-[1a,2b,3a,4b(1E,3E),4ab,8aa]]-
- 1,2,3-Naphthalenetriol,decahydro-4-[(1E,3E)-5-hydroxy-3-methyl-1,3-pentadienyl]-3,4a,8,8-tetramethyl-,(1R,2S,3S,4R,4aS,8aS)- (9CI)
- Sterebin E
- 1,2,3-Naphthalenetriol, decahydro-4-[(1E,3E)-5-hydroxy-3-methyl-1,3-pentadien-1-yl]-3,4a,8,8-tetramethyl-, (1R,2S,3S,4R,4aS,8aS)-
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
Sterebin E REF: BP-BP4932CAS: 114343-74-7 | 95%~99% | 557.00 €~897.00 € | Thu 09 Jan 25 | |
Sterebin E REF: TM-TN2235CAS: 114343-74-7 | 98% | 958.00 €~1,307.00 € | Thu 09 Jan 25 | |
Sterebin E REF: 3D-PEA34374CAS: 114343-74-7 | Min. 95% | To inquire | Tue 18 Feb 25 |
Sterebin E
CAS:114343-74-7
Sterebin E may have anti-inflammatory activity.
Formula:
C20H34O4
Purity:
98%
Color and Shape:
Solid
Molecular weight:
338.48
Ref: TM-TN2235
5mg | 958.00 € | ||
1mL*10mM (DMSO) | 1,307.00 € |
Estimated delivery in United States, on Thursday 9 Jan 2025
Sterebin E
CAS:114343-74-7
Sterebin E is an analog of a kinase inhibitor that has shown promising anticancer activity. …
Formula:
C20H34O4
Purity:
Min. 95%
Molecular weight:
338.5 g/mol
Ref: 3D-PEA34374
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Feb 2025